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The aim of this study was to compare the effect of treatment with lamotrigine (LTG) or carbamazepine (CBZ) on health-related
quality of life (HRQOL) and to demonstrate the use of the SEALS Inventory as a comparative tool in clinical trials.
Two hundred and sixty patients with newly diagnosed epilepsy were randomized to 48 weeks of treatment with LTG (n = 131)
or CBZ (n = 129). HRQOL was measured at baseline and weeks 4, 12, 24, and 48 using the modified Side Effect and Life
Satisfaction (SEALS) Inventory—a 38-item questionnaire divided into five subscales: Worry, Temper, Cognition, Dysphoria,
and Tiredness.
Overall, SEALS scores in the LTG group decreased (improved) significantly from baseline (P = 0.001). The LTG group had
improvement in all five subscales over the 48 weeks of the study. CBZ patients had significantly worse SEALS scores than LTG
patients at week 4 (P < 0.038). There was no significant change (positive or negative) in subsequent SEALS assessments.
Analysis of SEALS data by subscale showed that the the CBZ group experienced more cognitive side-effects in general and
more general changes in energy levels and affect during the first 4 weeks of treatment. These changes may help explain the
difference in study completion rate: LTG 65%, CBZ 51% (P = 0.018).
LTG offers the patient with newly diagnosed epilepsy significant benefits of greater tolerability and better health-related quality
of life compared with CBZ. The SEALS Inventory is an effective tool for use in clinical trials of AEDs; it was a better predictor
of trial completion than seizure counts, and used as a covariate enabled better detection of treatment effects. In general practice,
the use of the SEALS Inventory to assess HRQOL has the potential to improve quality of care for people with epilepsy.
c© 2000 BEA Trading Ltd
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INTRODUCTION
Health-related quality of life (HRQOL) assessments
are critical to increasing our understanding of how
patients live with a treatable but potentiality debilitat-
ing chronic condition. HRQOL studies in epilepsy are
important because of the high potential for adverse ef-
fects from chronic anticonvulsant therapy and because
the disease-related psychosocial pathology of epilepsy
can be more handicapping than the seizures1.
Recent European HRQOL studies have provided
interesting and similar results. One HRQOL survey
of 696 people with epilepsy in the United King-
dom found a high incidence of depression (25%) and
anxiety (39%), notwithstanding that most of the re-
spondents were judged reasonably well-controlled2.
Additionally, more than a third said they felt stigma-
tized by their disease. A larger cross-sectional survey
of 5211 people with epilepsy in 15 European countries
found a high incidence of side effects from antiepilep-
tic drug (AED) therapy. Further, a large percentage of
respondents stated that life with epilepsy negatively af-
fected their self image, overall health, social activities,
standard of living, plans for the future, ability to work
in paid employment, and relationships with friends
and family members3. More than half (51%) of the
people surveyed felt stigmatized by their disease; of
these, 18% felt highly stigmatized. Respondents with
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frequent seizures (≥1 per month) and seizures of more
than one type were more likely to report psychoso-
cial problems than those with less frequent seizures
and those with only one type of seizure. The inves-
tigators concluded that the three keys to improved
HRQOL for people with epilepsy are better seizure
control, more tolerable AED therapy, and alleviation
of disease-associated stigma.
We present HRQOL data from a previously pub-
lished study—a 48-week randomized, double-blind
comparison of lamotrigine (LTG) and carbamazepine
(CBZ) that included 260 newly diagnosed patients
with partial or generalized tonic–clonic seizures, or
both4. The proportions of patients who were seizure
free during the last 24 weeks of the study were virtu-
ally identical—LTG 39%, CBZ 38%—and no differ-
ences in efficacy were identified by seizure type. How-
ever, LTG was better tolerated as shown by greater
patient completion. In the LTG treatment group, 65%
completed the 48-week study, compared with 51% of
the CBZ group (P = 0.018). The greatest differ-
ence between groups was in the proportion of patients
withdrawn for adverse events: LTG 15%, CBZ 27%
(P = 0.0138). The present study evaluates one of
the HRQOL measures used in the comparison of LTG
and CBZ, the SEALS Inventory. The relationship be-
tween SEALS scores, seizure control, and tolerability
of antiepileptic therapy is assessed.
MATERIALS AND METHODS
The SEALS Inventory
HRQOL was assessed with the Side Effect and Life
Satisfaction (SEALS) Inventory5, a modified version
of a 50-item self-report questionnaire developed by
Brown and Tomlinson6 to assess the interaction of
chronic anticonvulsant therapy and psychosocial func-
tioning. The SEALS Inventory comprises 38 questions
chosen from factor analysis of data from 923 subjects.
The 38 questions are grouped in five subscales: Worry,
Temper, Cognition, Dysphoria, and Tiredness. Each
item is scored on a 4-point system (0 = never, 1 =
occasionally, 2 = sometimes, 3 = many times). The
score for each subscale is the point total for the items
in that subscale, and total SEALS score is the sum
of the scores of the five subscales. Lower scores indi-
cate fewer symptoms and therefore a higher HRQOL.
Missing values were imputed from the average of the
other response scores within the specific subscale.
Data collection
The design, conduct, and clinical outcomes of this 48-
week study have been previously reported3. Newly di-
agnosed patients were randomized at screen to treat-
ment with either CBZ (n = 129) or LTG (n = 131).
Patients completed the SEALS Inventory at baseline
and at weeks 4, 12, 24, and 48.
Data analysis
Simple summary statistics were calculated by visit
for patients who completed the study and by time
of dropout for those who withdrew early. The data
were analysed using a repeated measures approach
developed specifically for data that may be affected
by dropout rates7. This approach allows estimation of
treatment differences adjusted for any dropout effect,
and a significance test can be performed to assess the
null hypothesis that results are not affected by dropout
rate.
SEALS scores were the dependent variable with co-
variates of time, treatment, and log baseline seizure
count. Time was included as a categorical variable
with five levels—weeks 0, 4, 12, 24 and 48—to pro-
vide dropout-adjusted estimates of SEALS scores. A
maximum likelihood approach was used to estimate
the treatment effect and other parameters of interest.
For the SEALS subscales, mean scores for each
treatment group were calculated at each visit, after us-
ing last observation carried forward as a crude method
of accounting for the patients who withdrew from the
trial.
To determine the effect of baseline SEALS scores
on the interpretation of the main endpoint in the trial,
withdrawal from the study, a survival analysis using
the proportional hazards model was carried out. In
the original report of this trial3, this analysis was per-
formed using treatment and baseline seizure count as
covariates. The analysis presented here uses the base-
line SEALS score as a covariate, in addition to the
other two variables.
All data analyses were carried out with SASr soft-
ware, predominantly using the interactive matrix lan-
guage8.
RESULTS
Summary statistics for SEALS scores in both treat-
ment groups are shown in Table 1. Patients in both
groups who completed the study appear to have had
lower (better) SEALS scores at screen than patients
who dropped out. Of patients who completed the
study, mean SEALS scores in the LTG group de-
creased (improved) by four points over the course of
the study. The interpretation of the significance of
this, however, depends on consideration of the dropout
data.
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Table 1: Mean SEALS scores (SD) by time of withdrawal.
Withdrew Withdrew Withdrew Withdrew Completed
before before before before the 48-week
week 4 week 12 week 24 week 48 study
Lamotrigine
No. of patients 20 11 0 5 73
Score at screen 54 (20) 47 (21) 66 (23) 45 (22)
at week 4 42 (19) 55 (21) 42 (20)
at week 12 48 (19) 39 (20)
at week 24 64 (29) 40 (21)
at week 48 41 (21)
Carbamazepine
No of patients 20 13 5 3 60
Score at screen 47 (23) 41 (17) 48 (8) 43 (31) 38 (17)
at week 4 54 (20) 50 (10) 41 (21) 38 (20)
at week 12 50 (17) 54 (16) 36 (19)
at week 24 49 (16) 37 (22)
at week 48 37 (20)
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Fig. 1: Estimated change from baseline in SEALS scores
for lamotrigine (solid line) and carbamazepine (dotted line)
patients.
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Fig. 2: Kaplan Meler plot showing estimated percentage
of patients retained on lamotrigine (dotted line) and carba-
mazepine (solid line).
Changes in SEALS score over the 48 weeks of
the trial
Figure 1 shows change in SEALS score from base-
line, estimated by repeated measures analysis and ad-
justed for the effect of dropouts. There were signifi-
cant changes in score within both groups over time.
Patients randomized to LTG had significantly higher
(worse) SEALS scores at baseline than patients in the
CBZ group (P = 0.021). Over the duration of the
trial, SEALS scores in the LTG group improved sig-
nificantly from baseline (P < 0.001), but with no sig-
nificant change between any of the on treatment visits
(P = 0.88). On average, patients in the CBZ group
had significantly worse SEALS scores at week 4 than
at baseline (P = 0.038), but at subsequent assess-
ments, no significant change from baseline was ob-
served (P = 0.394).
SEALS subscales
Patients taking LTG showed improvement on all five
subscales, over the 48-week trial. The biggest im-
provement appeared to be in the Cognition subscale.
Overall, patients randomized to CBZ showed deterio-
ration in the Cognition, Dysphoria, and Tiredness sub-
scales. Improvements observed among CBZ patients
in the Temper and Worry subscales were smaller than
those observed in the LTG patients.
Relationship between SEALS scores and
dropouts
In both treatment groups, patients who completed the
full 48 weeks of therapy had lower (better) base-
line SEALS scores than patients who dropped out.
Dropouts also appeared to have worsening SEALS
scores at the visits leading up to withdrawal. A re-
peated measures model was used to test whether wors-
ening SEALS scores were associated with an in-
378 R. Gillham et al.
Table 2: Treatment assignment, baseline seizure rate, and baseline SEALS score as risk factors for withdrawal.
Excluding SEALS data Including SEALS data
Risk factor Hazard ratioa P-value Hazard ratio P-value
Treatment assignment 1.60 0.018 1.82 0.0057
Baseline seizure rate 1.009 0.017 1.007 0.058
Baseline SEALS score 1.014 0.0067
a The hazard ratio estimates the risk of early withdrawal, at any time, from the carbamazepine group, compared with the lamotrigine group,
e.g. in the analysis excluding SEALS data, the hazard ratio of 1.60 indicates a 60% greater chance of early withdrawal among patients in the
carbamazepine group.
creased likelihood of dropping out; the resulting P-
value was 0.00017, indicating a strong positive rela-
tionship.
Withdrawal rates differed between treatment groups
(P = 0.018) and are shown in Fig. 2. Patients taking
CBZ were significantly more likely to drop out. Re-
sults of the analysis of withdrawal data, taking account
of baseline SEALS scores, are shown in Table 2. The
use of baseline SEALS scores increased our ability to
predict patient withdrawal (P = 0.0024). The hazard
ratio associated with each treatment term estimates the
risk of dropping out at any time in the CBZ group,
compared with the LTG group. In the analysis ignor-
ing the SEALS scores, it appeared that CBZ patients
had a 60% greater risk than LTG patients of dropping
out at any time. However, when SEALS scores were
added to the model, the risk of withdrawal increased
to 82%.
DISCUSSION
Research has shown that HRQOL assessments have
the potential to improve the quality of care in chronic
diseases and conditions. Unfortunately, such assess-
ments are not routinely part of a clinical study, nor
are they routinely used in the practical management
of epilepsy. This is unfortunate not only for the patient
whose day-to-day experience of epilepsy may be sub-
stantially complicated by disease-related psychosocial
impairment and adverse effects of drug therapy, but
also for the researcher, who does not employ a useful
tool for gauging the therapeutic value of various treat-
ment options.
In this trial, LTG was better tolerated than CBZ,
as evidenced by the fact that more patients in the
LTG group completed the study: 65% vs. 51% (P =
0.018)3. Examining adverse events alone, we found
that more patients in the CBZ group withdrew due
to toxicity. The most common event leading to with-
drawal in either group was rash: LTG 9%, CBZ 13%;
but the only event occurring with significantly greater
frequency in either group was somnolence: LTG 12%,
CBZ 22% (P < 0.05)3. When HRQOL data are con-
sidered, however, patients in the CBZ group are seen
to have had more cognitive side-effects in general,
as recorded by the SEALS Cognition subscale, and
more general changes in energy levels and affect, as
recorded by the Dysphoria and Tiredness scales dur-
ing the first 4 weeks of treatment. In contrast, the LTG
group had significantly improved HRQOL over the
48-week study.
Higher (worse) SEALS scores were associated with
a significantly increased risk of early withdrawal. In-
terestingly, more patients in the LTG group com-
pleted the study, despite having higher (worse) base-
line SEALS scores. This may be further evidence of
the greater tolerability of LTG, but we must also con-
sider the effect the difference might have had on time
to withdrawal. To this end, withdrawal rates were re-
calculated to include baseline SEALS scores, and it
now appears that the treatment effect, in terms of time
to withdrawal, may have been larger than originally in-
dicated. Re-analysis also demonstrated that addition of
the SEALS term as a covariate increased the precision
of the treatment difference estimates.
In randomized comparative trials, there is a risk of
error when only those patients who complete the study
are evaluated. In the present study, when patients who
withdrew and had higher (worse) SEALS scores were
excluded from the treatment-group means calculation,
mean scores improved with each dropout. Therefore,
we recommend follow-up of withdrawn patients af-
ter the randomized drug is discontinued when future
studies of a similar nature are undertaken. Intent-to-
treat analyses can then be completed for all patients to
avoid the risks associated with ignoring dropouts.
Our findings are similar to those of Steiner et al.9
who conducted a double-blind comparison of LTG and
phenytoin. In that trial, 181 newly diagnosed patients
were randomized to treatment for 48 weeks. No dif-
ferences were found in the proportion of seizure-free
patients, but LTG was better tolerated. Patients in the
LTG group had a higher incidence of rash; patients
in the phenytoin group had higher rates of asthenia
somnolence, and ataxia. In the LTG group, SEALS
scores improved for Cognition, Tiredness, Worry, and
Temper subscales, and remained stable for Dyspho-
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ria. In the phenytoin group, SEALS scores worsened
over time for the Cognition, Dysphoria and Tired-
ness subscales. The resulting 4-point difference in
SEALS score between groups was statistically signifi-
cant (P = 0.002).
Statistically significant changes in SEALS scores,
both within and between treatment groups, may be
considered to be of little value without considering
whether they are clinically relevant to the individ-
ual patient. However, since the SEALS Inventory is
a self-report scale it is reasonable to assume that any
change in score is of significance to the patient since
the patient is reporting the change. This is an impor-
tant point which highlights the value of self-report
measures in outcome studies. Measures which may
be more objective, for example seizure counts, may
be harder to interpret because the impact of small but
statistically significant changes on the patient is not
known. A cross-sectional analysis of the present study
at week 4 showed that patients with seizures had a
13-point higher (worse) SEALS score than those who
were seizure free (P = 0.0011)10. SEALS scores
also worsened among patients who reported side ef-
fects from therapy. For each additional side effect,
SEALS score worsened by an average of 3.4 points
(P = 0.0010). As the SEALS is a self-report measure
it may be assumed that a difference of 3.4 points is
both clinically and statistically significant.
We conclude that LTG offers the newly diagnosed
patient with partial and/or generalized tonic–clonic
seizures significant benefits of greater tolerability and
better quality of life, compared with CBZ. The tolera-
bility of LTG can be improved with respect to rash by
initiating therapy at a lower dose than the dose used in
the present study and then slowly titrating upward un-
til complete or maximum seizure control is achieved.
We also make the general observation that using the
SEALS Inventory in trials of new AEDs offers the re-
searcher greater precision in the measurement of treat-
ment effects. Clinicians who use the SEALS Inventory
in their everyday practice have a tool that allows for
a more sensitive evaluation of an individual patient’s
well-being and that offers the possibility of a better
quality of care for people with epilepsy.
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